Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics Innsbruck, Austria, April 15, 2025 – Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that the companies have signed a Non-Exclusive License…
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information